Clomipramine Hydrochloride is the hydrochloride salt form of clomipramine, a tertiary amine salt derivative of dibenzazepine. Clomipramine hydrochloride is a tricyclic antidepressant that acts by reducing the re-uptake of norepinephrine and serotonin in the central nervous system, thereby enhancing the effects of these neurotransmitters. This drug also binds to alpha-adrenergic, histaminergic, and cholinergic receptors which are responsible for the many side effects seen with this agent.
Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -
Clomipramine Hydrochloride
Drug Overview
What is Clomipramine Hydrochloride?
To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).
Request Your Assessment
Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.
View Inquiry List →Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
Regulatory Framework
Assessment Methodology
Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.
EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)
Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.
PIC/S – Shared Facilities and Contamination Control Guidance
Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.
ICH Q9 – Quality Risk Management
Provides a structured methodology for risk identification, assessment, control, communication, and review.
ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)
Applied for compounds with potential mutagenic or genotoxic concerns.
Risk-Based Toxicological Assessment
Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.
Weight-of-Evidence (WoE) Approach
Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.
How We Work
Report Preparation Process
Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.
Comprehensive Data Review
Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.
Scientific Evaluation
Identification of critical endpoints and selection of appropriate exposure limits.
PDE / HBEL Derivation
Transparent and scientifically justified calculations aligned with global toxicological principles.
Ex-Agency Expert Review (Our Differentiator)
Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.
Final Report Delivery
Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).
Ex-Agency Advantage
Why Masuu Global?
Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.
Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.
Inspection-ready reports — scientifically defensible and audit-prepared from day one.
Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).
Practical implementation recommendations that translate science into actionable contamination control.
Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.
Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.
Ready to request your assessment?
Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.
Frequently Asked Questions
Clomipramine Hydrochloride is the hydrochloride salt of clomipramine and the form used in capsules, tablets and some injections. Because exposure limits may be expressed for either the salt or the base, the assessment should state which basis is used. The tricyclic antidepressant pharmacology of clomipramine informs the choice of critical effect.
A PDE or ADE sets a health-based limit on daily exposure to Clomipramine Hydrochloride from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.
A Masuu Global report for Clomipramine Hydrochloride presents the scientific rationale, the calculations behind each exposure limit, and clear recommendations for use in risk assessment. Reports are prepared by certified toxicologists and designed to be regulatory-ready, so quality, safety and regulatory teams can follow and review how each value was derived.
The OEL gives a scientific benchmark for evaluating workplace exposure. Combined with exposure monitoring, engineering controls, and safe handling procedures, it helps organizations manage inhalation risk during operations such as dispensing, granulation, and cleaning. It should sit within a broader occupational risk assessment.
Where pharmacological activity is relevant for Clomipramine Hydrochloride, the dose at which intended or unintended pharmacological effects occur can be an important point of departure. The assessment considers whether such effects could arise in patients exposed through carryover or in workers exposed during handling, alongside the wider toxicological evidence, before the critical effect is selected.
An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.
An OEB places Clomipramine Hydrochloride in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.
An assessment of Clomipramine Hydrochloride should be reviewed when new toxicological or clinical data become available, when the way the substance is used or manufactured changes, or when relevant regulatory guidance is updated. Periodic review helps confirm that the exposure limits and the conclusions drawn from them remain scientifically justified and current.
Yes, where relevant. For a substance used in medicines, human dose information, including the lowest therapeutic dose and reported adverse effects, can provide a useful basis for a health-based limit for Clomipramine Hydrochloride. It is weighed together with non-clinical data, and appropriate adjustment factors are applied and documented in the report.
It can. Handling Clomipramine Hydrochloride as a fine powder, a granulated material or a solution changes how readily the material can become airborne and how workers may be exposed. Dusty powders generally raise greater inhalation concern than wetted or granulated forms, so physical form is considered when selecting containment, ventilation and personal protective equipment.
Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.
Use the Request Your Assessment option on this page and add Clomipramine Hydrochloride to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.
